Neil Kumar, Ph.D.
President and Chairman of the Board
Dr. Kumar is the chief executive officer and founder of BridgeBio Pharma LLC, a company focused on developing novel therapies for genetic diseases. Prior to founding BridgeBio, he was a principal at Third Rock Ventures, a healthcare-focused venture firm, where he supported and managed various portfolio companies in addition to overseeing new company formation and due diligence. He also held the role of vice president of business development and operations for MyoKardia, a precision medicine company working on targeted therapies for rare cardiovascular diseases. Before joining Third Rock, Dr. Kumar was associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Previously, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Dr. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.